Fig. 1.
Disposition of all participants through year 5 of the FREEDOM Extension. All women who completed FREEDOM (i.e., completed their 3-year visit, did not discontinue investigation product, and did not miss more than one dose) were eligible to participate in the Extension. aTwo women who discontinued denosumab also entered the Extension in the long-term denosumab group [2]